<DOC>
	<DOCNO>NCT01411423</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient administer Nexavar unresectable advance renal cell carcinoma ( RCC ) . The objective study ass safety effectiveness Nexavar real-life practice condition . This study case investigation enrollment period 15 month , patient receive Nexavar recruit follow one year since start Nexavar administration .</brief_summary>
	<brief_title>Nexavar Post-marketing Surveillance Renal Cell Carcinoma Japan</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients receive Nexavar unresectable advance renal cell carcinoma Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Nexavar</keyword>
	<keyword>Unresectable advance renal cell carcinoma</keyword>
</DOC>